Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02033382 · ClinicalTrials.gov registry record
Biomarkers in First Episode Schizophrenia
A clinical trial of Schizophrenia and Schizophreniform Disorder, sponsored by NYU Langone Health.
- Completed
- Registry status
- 165
- Enrollment target
- 1
- Study location
NCT02033382 is a study of Schizophrenia and Schizophreniform Disorder that has completed, run by NYU Langone Health. The registered enrollment target is 165 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02033382, a study of Schizophrenia and Schizophreniform Disorder, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after initiation of antipsychotic medication
Conditions Studied
Study Locations (1)
New York
- Bellevue Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02033382
The ClinicalTrials.gov registry entry for NCT02033382 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (24% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.
NCT02033382 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02033382 about?
NCT02033382 is a clinical study titled "Biomarkers in First Episode Schizophrenia". This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after initiation of antipsychotic medication
What is the current status of trial NCT02033382?
This trial is currently completed. The enrollment target is 165 participants. The study started on 2012-07. Estimated completion is 2014-12.
What conditions does trial NCT02033382 study?
This clinical trial studies the following conditions: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type.
Who is sponsoring clinical trial NCT02033382?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02033382 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.